vs
FRP HOLDINGS, INC.（FRPH）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是FRP HOLDINGS, INC.的1.8倍（$19.6M vs $10.9M），FRP HOLDINGS, INC.净利率更高（1.3% vs -177.4%，领先178.7%），FRP HOLDINGS, INC.同比增速更快（3.6% vs -11.5%），FRP HOLDINGS, INC.自由现金流更多（$-21.5M vs $-23.1M），过去两年FRP HOLDINGS, INC.的营收复合增速更高（3.8% vs -12.2%）
FRP咨询是总部位于英国的商业咨询公司，核心业务涵盖企业重组、企业融资、债务咨询、法务会计及各类财务咨询服务，是英国规模最大的企业重组领域专业机构之一。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FRPH vs LAB — 直观对比
营收规模更大
LAB
是对方的1.8倍
$10.9M
营收增速更快
FRPH
高出15.1%
-11.5%
净利率更高
FRPH
高出178.7%
-177.4%
自由现金流更多
FRPH
多$1.6M
$-23.1M
两年增速更快
FRPH
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.9M | $19.6M |
| 净利润 | $139.0K | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 15.4% | -168.5% |
| 净利率 | 1.3% | -177.4% |
| 营收同比 | 3.6% | -11.5% |
| 净利润同比 | -91.8% | -28.8% |
| 每股收益（稀释后） | $0.03 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRPHLAB
| Q4 25 | $10.9M | — | ||
| Q3 25 | $10.8M | $19.6M | ||
| Q2 25 | $10.8M | $21.8M | ||
| Q1 25 | $10.3M | $40.8M | ||
| Q4 24 | $10.5M | — | ||
| Q3 24 | $10.6M | $22.1M | ||
| Q2 24 | $10.5M | $22.5M | ||
| Q1 24 | $10.1M | $45.5M |
净利润FRPHLAB
| Q4 25 | $139.0K | — | ||
| Q3 25 | $662.0K | $-34.7M | ||
| Q2 25 | $578.0K | $-33.5M | ||
| Q1 25 | $1.7M | $-26.0M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $1.4M | $-26.9M | ||
| Q2 24 | $2.0M | $-45.7M | ||
| Q1 24 | $1.3M | $-32.2M |
毛利率FRPHLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率FRPHLAB
| Q4 25 | 15.4% | — | ||
| Q3 25 | 12.6% | -168.5% | ||
| Q2 25 | 15.3% | -118.1% | ||
| Q1 25 | 22.6% | -80.8% | ||
| Q4 24 | 27.7% | — | ||
| Q3 24 | 29.0% | -120.9% | ||
| Q2 24 | 26.9% | -134.5% | ||
| Q1 24 | 28.4% | -132.2% |
净利率FRPHLAB
| Q4 25 | 1.3% | — | ||
| Q3 25 | 6.1% | -177.4% | ||
| Q2 25 | 5.3% | -153.7% | ||
| Q1 25 | 16.6% | -63.8% | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 12.8% | -122.0% | ||
| Q2 24 | 19.5% | -203.3% | ||
| Q1 24 | 12.8% | -70.6% |
每股收益（稀释后）FRPHLAB
| Q4 25 | $0.03 | — | ||
| Q3 25 | $0.03 | $-0.09 | ||
| Q2 25 | $0.03 | $-0.09 | ||
| Q1 25 | $0.09 | $-0.07 | ||
| Q4 24 | $0.09 | — | ||
| Q3 24 | $0.07 | $-0.07 | ||
| Q2 24 | $0.11 | $-0.12 | ||
| Q1 24 | $0.07 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $192.6M | — |
| 股东权益账面价值 | $428.5M | $399.7M |
| 总资产 | $735.1M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资FRPHLAB
| Q4 25 | — | — | ||
| Q3 25 | $134.9M | $129.4M | ||
| Q2 25 | $153.2M | $158.6M | ||
| Q1 25 | $142.9M | $150.9M | ||
| Q4 24 | $148.6M | — | ||
| Q3 24 | $144.7M | $210.6M | ||
| Q2 24 | $156.9M | $269.8M | ||
| Q1 24 | $152.5M | $287.1M |
总债务FRPHLAB
| Q4 25 | $192.6M | — | ||
| Q3 25 | $185.3M | — | ||
| Q2 25 | $180.4M | — | ||
| Q1 25 | $178.3M | — | ||
| Q4 24 | $178.9M | — | ||
| Q3 24 | $178.8M | $55.2M | ||
| Q2 24 | $178.8M | $55.1M | ||
| Q1 24 | $178.7M | $55.0M |
股东权益FRPHLAB
| Q4 25 | $428.5M | — | ||
| Q3 25 | $427.7M | $399.7M | ||
| Q2 25 | $426.7M | $424.5M | ||
| Q1 25 | $425.2M | $454.6M | ||
| Q4 24 | $423.1M | — | ||
| Q3 24 | $420.9M | $489.3M | ||
| Q2 24 | $419.1M | $510.3M | ||
| Q1 24 | $416.1M | $577.3M |
总资产FRPHLAB
| Q4 25 | $735.1M | — | ||
| Q3 25 | $731.3M | $539.6M | ||
| Q2 25 | $722.8M | $557.0M | ||
| Q1 25 | $717.1M | $579.6M | ||
| Q4 24 | $728.5M | — | ||
| Q3 24 | $726.9M | $681.5M | ||
| Q2 24 | $711.9M | $708.7M | ||
| Q1 24 | $705.7M | $777.7M |
负债/权益比FRPHLAB
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.42× | — | ||
| Q3 24 | 0.42× | 0.11× | ||
| Q2 24 | 0.43× | 0.11× | ||
| Q1 24 | 0.43× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-21.5M | $-23.1M |
| 自由现金流率自由现金流/营收 | -196.6% | -118.1% |
| 资本支出强度资本支出/营收 | 468.5% | 4.5% |
| 现金转化率经营现金流/净利润 | 213.50× | — |
| 过去12个月自由现金流最近4个季度 | $-34.4M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FRPHLAB
| Q4 25 | $29.7M | — | ||
| Q3 25 | $8.1M | $-22.2M | ||
| Q2 25 | $8.7M | $-20.7M | ||
| Q1 25 | $4.5M | $-30.3M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $6.3M | $-27.9M | ||
| Q2 24 | $12.2M | $-39.0M | ||
| Q1 24 | $2.9M | $-62.5M |
自由现金流FRPHLAB
| Q4 25 | $-21.5M | — | ||
| Q3 25 | $-16.9M | $-23.1M | ||
| Q2 25 | $2.6M | $-22.6M | ||
| Q1 25 | $1.4M | $-35.3M | ||
| Q4 24 | $-22.2M | — | ||
| Q3 24 | $-28.2M | $-30.1M | ||
| Q2 24 | $5.9M | $-41.0M | ||
| Q1 24 | $-3.3M | $-63.3M |
自由现金流率FRPHLAB
| Q4 25 | -196.6% | — | ||
| Q3 25 | -157.0% | -118.1% | ||
| Q2 25 | 24.0% | -103.6% | ||
| Q1 25 | 13.6% | -86.6% | ||
| Q4 24 | -210.9% | — | ||
| Q3 24 | -265.7% | -136.4% | ||
| Q2 24 | 56.0% | -182.2% | ||
| Q1 24 | -32.6% | -138.9% |
资本支出强度FRPHLAB
| Q4 25 | 468.5% | — | ||
| Q3 25 | 232.0% | 4.5% | ||
| Q2 25 | 55.9% | 8.7% | ||
| Q1 25 | 30.1% | 12.4% | ||
| Q4 24 | 486.1% | — | ||
| Q3 24 | 325.1% | 10.2% | ||
| Q2 24 | 60.3% | 8.6% | ||
| Q1 24 | 61.2% | 1.7% |
现金转化率FRPHLAB
| Q4 25 | 213.50× | — | ||
| Q3 25 | 12.21× | — | ||
| Q2 25 | 15.00× | — | ||
| Q1 25 | 2.63× | — | ||
| Q4 24 | 17.18× | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 5.96× | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRPH
| Other | $5.6M | 51% |
| Multifamily Segment | $5.3M | 49% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
